Targeting signal transducer and activator of transcription signaling pathway in leukemias

Journal of Clinical Oncology

Volumn 27, Issue 26, 2009, Pages 4422-4432

  Benekli, Mustafa ^a   Baumann, Heinz ^a   Wetzler, Meir ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ANTISENSE OLIGONUCLEOTIDE; ARSENIC TRIOXIDE; BCR ABL PROTEIN; CD135 ANTIGEN; CD20 ANTIBODY; CYTOKINE INDUCIBLE SH2 CONTAINING PROTEIN; FINGOLIMOD; FORSKOLIN; GTP 14564; INDIRUBIN; IS3 295; ISIS 345794; ISOPROTEIN; ISS 610; JANUS KINASE 2; JANUS KINASE INHIBITOR; JSI 124; LESTAURTINIB; MIDOSTAURIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PEPTIDOMIMETIC AGENT; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN; PROTEIN P190; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; STAT BETA PROTEIN; STAT PROTEIN; STAT3 PROTEIN; SU 5614; SUPPRESSOR OF CYTOKINE SIGNALING; TANESPIMYCIN; TRANSCRIPTION FACTOR ETV6; UNCLASSIFIED DRUG; UNINDEXED DRUG; STAT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; BINDING SITE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL TRIAL; DNA BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MYELOBLAST; MYELODYSPLASTIC SYNDROME; NEGATIVE FEEDBACK; NUCLEOCYTOPLASMIC TRANSPORT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION; BIOLOGICAL MODEL; DRUG EFFECT; DRUG THERAPY; METABOLISM; METHODOLOGY; PATHOLOGY; PHOSPHORYLATION;

CELL TRANSFORMATION, NEOPLASTIC; DRUG THERAPY; HUMANS; LEUKEMIA; MODELS, BIOLOGICAL; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 70349323403     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.3264     Document Type: Review

References (118)

1. Darnell JE Jr: STATs and gene regulation. Science 277:1630-1635, 1997
2. National Center for Biotechnology Information: NCBI genome resource guides. http://www.ncbi.nlm.nih.gov/genome/guide/
3. Chen X, Vinkemeier U, Zhao Y, et al: Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93:827-839, 1998
4. Becker S, Bernd G, Muller CW: Threedimensional structure of the Stat3 beta homodimer bound to DNA. Nature 394:145-151, 1998
5. Chakraborty A, White SM, Schaefer TS, et al: Granulocyte colony-stimulating factor activation of STAT3 alpha and STAT3 beta in immature normal and leukemic human myeloid cells. Blood 88:2442-2449, 1996
6. Azam M, Lee C, Strehlow I, et al: Functionally distinct isoforms of STAT5 are generated by protein processing. Immunity 6:691-701, 1997
7. Xia Z, Salzler RR, Kunz DP, et al: A novel serine-dependent proteolytic activity is responsible for truncated signal transducer and activator of transcription proteins in acute myeloid leukemia blasts. Cancer Res 61:1747-1753, 2001
8. Schuster B, Hendry L, Byers H, et al: Purification and identification of the STAT5 protease in myeloid cells. Biochem J 404:81-87, 2007
9. Shuai K, Liu B: Regulation of JAK-STAT signaling in the immune system. Nat Rev Immunol 3:900-911, 2003
10. Ghoshal Gupta S, Baumann H, Wetzler M: Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia. Leuk Res 32:1005-1014, 2008
11. Lim CP, Cao X: Structure, function, and regulation of STAT proteins. Mol Biosyst 2:536-550, 2006
12. Krebs DL, Hilton DJ: SOCS proteins: Negative regulators of cytokine signaling. Stem Cells 19:378-387, 2001
13. Ram PA, Waxman DJ: Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J Biol Chem 272:17694-17702, 1997
14. Woetmann A, Nielsen M, Christensen ST, et al: Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. Proc Natl Acad Sci U S A 96:10620-10625, 1999
15. Jackson PK: A new RING for SUMO: Wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev 15:3053-3058, 2001
16. Shuai K, Liu B: Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 5:593-605, 2005
17. Kim TK, Maniatis T: Regulation of interferongamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 273:1717-1719, 1996
18. Tanaka T, Soriano MA, Grusby MJ: SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity 22:729-736, 2005
19. Malakhova OA, Yan M, Malakhov MP, et al: Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev 17:455-460, 2003
20. Ungureanu D, Vanhatupa S, Grönholm J, et al: SUMO-1 conjugation selectively modulates STAT1-mediated gene responses. Blood 106:224-226, 2005
21. Collum RG, Brutsaert S, Lee G, et al: A Stat3-interacting protein (StIP1) regulates cytokine signal transduction. Proc Natl Acad Sci U S A 97: 10120-10125, 2000
22. Decker T, Kovarik P: Transcription factor activity of STAT proteins: Structural requirements and regulation by phosphorylation and interacting proteins. Cell Mol Life Sci 55:1535-1546, 1999
23. Reich NC, Liu L: Tracking STAT nuclear traffic. Nat Rev Immunol 6:602-612, 2006
24. Pranada AL, Metz S, Herrmann A, et al: Real time analysis of STAT3 nucleocytoplasmic shuttling. J Biol Chem 279:15114-15123, 2004
25. Marg A, Shan Y, Meyer T, et al: Nucleocytoplasmic shuttling by nucleoporins Nup153 and Nup214 and CRM1-dependent nuclear export control the subcellular distribution of latent Stat1. J Cell Biol 165:823-833, 2004
26. Liu L, McBride KM, Reich NC: STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci U S A 102:8150-8155, 2005
27. Lödige I, Marg A, Wiesner B, et al: Nuclear export determines the cytokine sensitivity of STAT transcription factors. J Biol Chem 280:43087-43099, 2005
28. Herrmann A, Vogt M, Monnigmann M, et al: Nucleocytoplasmic shuttling of persistently activated STAT. J Cell Sci 120:3249-3261, 2007
29. ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, et al: Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 22:5662-5668, 2002
30. Huang Y, Qiu J, Dong S, et al: Stat3 isoforms, alpha and beta, demonstrate distinct intracellular dynamics with prolonged nuclear retention of Stat3beta mapping to its unique C-terminal end. J Biol Chem 282:34958-34967, 2007
31. Benekli M, Baer MR, Baumann H, et al: Signal transducer and activator of transcription proteins in leukemias. Blood 101:2940-2954, 2003
32. Yu H, Jove R: The STATS of cancer: New molecular targets come of age. Nat Rev Cancer 4:97-105, 2004
33. Ilaria RL Jr, van Etten RA: P210 and P190(Bcr-Abl) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271:31704-31710, 1996
34. Frank DA, Varticovski L: Bcr-Abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 10:1724-1730, 1996
35. Bromberg JF, Horvath CM, Besser D, et al: Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 18:2553-2558, 1998
36. Gesbert F, Griffin JD: Bcr-Abl activates transcription of the Bcl-x gene through STAT5. Blood 96:2269-2276, 2000
37. L expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 3:299-305, 2000
38. L. J Exp Med 191: 977-984, 2000
39. Donato NJ, Wu JY, Zhang L, et al: Downregulation of interleukin-3/ granulocyte-macrophage colony-stimulating factor receptor beta-chain in Bcr-Abl (+) human leukemic cells: Association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after Bcr-Abl inhibition. Blood 97:2846-2853, 2001
40. Hynes NE, Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5:341-354, 2005
41. Ozawa Y, Williams AH, Estes ML, et al: Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk Res 32:893-903, 2008
42. Bromberg JF, Wrzeszczynska MH, Devgan G, et al: Stat3 as an oncogene. Cell 98:295-303, 1999
43. Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107: 351-362, 2001
44. Niu G, Wright KL, Ma Y, et al: Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25:7432-7440, 2005
45. Xu Q, Briggs J, Park S, et al: Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24:5552-5560, 2005
46. Grandage VL, Gale RE, Linch DC, et al: PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19:586-594, 2005
47. Harir N, Pecquet C, Kerenyi M, et al: Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood 109:1678-1686, 2007
48. Goh KC, Haque SJ, Williams BR: P38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J 18:5601-5608, 1999
49. Hayakawa F, Towatari M, Kiyoi H, et al: Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19:624-631, 2000
50. Niu G, Wright KL, Huang M, et al: Constitutive STAT3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene 21:2000-2008, 2002
51. Biethahn S, Alves F, Wilde S, et al: Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factorassociated signal transduction proteins of the JAK/ STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Exp Hematol 27:885-894, 1999
52. Spiekermann K, Biethahn S, Wilde S, et al: Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol 67:63-71, 2001
53. Aronica MG, Brizzi MF, Dentelli P, et al: P91 STAT1 activation in interleukin-3-stimulated primary acute myeloid leukemia cells. Oncogene 13:1017-1026, 1996
54. Gouilleux-Gruart V, Gouilleux F, Desaint C, et al: STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87:1692-1697, 1996
55. Weber-Nordt RM, Egen C, Wehinger J, et al: Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88:809-816, 1996
56. Hayakawa F, Towatari M, Iida H, et al: Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. Br J Haematol 101:521-528, 1998
57. Xia Z, Baer MR, Block AM, et al: Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res 58:3173-3180, 1998
58. Birkenkamp KU, Geugien M, Lemmink HH, et al: Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 15:1923-1931, 2001
59. Benekli M, Xia Z, Donohue KA, et al: Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99:252-257, 2002
60. Schuringa JJ, Wierenga AT, Kruijer W, et al: Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 95:3765-3770, 2000
61. Koistinen P, Saily M, Poromaa N, et al: Complex effects of interleukin 6 on clonogenic blast cell growth in acute myeloblastic leukemia. Acta Haematol 98:14-21, 1997
62. Frank DA, Mahajan S, Ritz J: B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 100:3140-3148, 1997
63. Sexl V, Piekorz R, Moriggl R, et al: Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of Stat5. Blood 96:2277-2283, 2000
64. Lacronique V, Boureux A, Valle VD, et al: A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309-1312, 1997
65. Lacronique V, Boureux A, Monni R, et al: Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 95:2076-2083, 2000
66. Carron C, Cormier F, Janin A, et al: TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95: 3891-3899, 2000
67. Schwaller J, Parganas E, Wang D, et al: STAT5 is essential for the myelo- and lymphoproliferative disease induced by TEL-JAK2. Mol Cell 6:693-704, 2000
68. Palmer AM, Mahajan S, Frank D, et al: The TEL-PDGFβR transforming protein activates STAT1. Blood 90:178a, 1997 (abstr)
69. Sternberg DW, Tomasson MH, Carroll M, et al: The TEL-PDGFR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. Blood 98:3390-3397, 2001
70. Choudhary C, Muller-Tidow C, Berdel WE, et al: Signal transduction of oncogenic Flt3. Int J Hematol 82:93-99, 2005
71. Spiekermann K, Dirschinger RJ, Schwab R, et al: The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 101:1494-1504, 2003
72. Choudhary C, Schwable J, Brandts C, et al: AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 106:265-273, 2005
73. Takahashi S, Harigae H, Kaku M, et al: Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5. Biochem Biophys Res Commun 316:85-92, 2004
74. Choudhary C, Brandts C, Schwable J, et al: Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 110:370-374, 2007
75. Pallis M, Seedhouse C, Grundy M, et al: Flow cytometric measurement of phosphorylated STAT5 in AML: Lack of specific association with FLT3 internal tandem duplications. Leuk Res 27:803-805, 2003
76. Dong S, Tweardy DJ: Cross-talk between retinoic acid and STAT3 signaling pathways in acute promyelocytic leukemia. Leukemia Lymphoma 44: 2023-2029, 2003
77. Arnould C, Philippe C, Bourdon V, et al: The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet 8:1741-1749, 1999
78. Dong S, Tweardy DJ: Interactions of STAT5b-RARα, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood 99:2637-2646, 2002
79. Maurer AB, Wichmann C, Gross A, et al: The Stat5-RARα fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood 99:2647-2652, 2002
80. Matikainen S, Ronni T, Lehtonen A, et al: Retinoic acid induces signal transducer and activator of transcription (STAT) 1, STAT2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. Cell Growth Differ 8:687-698, 1997
81. Dimberg A, Nilsson K, Oberg F: Phosphorylation-deficient Stat1 inhibits retinoic acidinduced differentiation and cell cycle arrest in U-937 monoblasts. Blood 96:2870-2878, 2000
82. Xia Z, Sait SN, Baer MR, et al: Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk Res 25:473-482, 2001
83. Jing N, Tweardy DJ: Targeting Stat3 in cancer therapy. Anticancer Drugs 16:601-607, 2005
84. Alas S, Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/ paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61:5137-5144, 2001
85. Meydan N, Grunberger T, Dadi H, et al: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379:645-648, 1996
86. Blaskovich MA, Sun J, Cantor A, et al: Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63:1270-1279, 2003
87. Sun J, Blaskovich MA, Jove R, et al: Cucurbitacin Q: A selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 24:3236-3245, 2005
88. Carroll M, Ohno-Jones S, Tamura S, et al: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins. Blood 90:4947-4952, 1997
89. Yao Q, Nishiuchi R, Kitamura T, et al: Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: The key role of the STAT5 signal transduction pathway. Leukemia 19:1605-1612, 2005
90. Propper DJ, McDonald AC, Man A, et al: Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19:1485-1492, 2001
91. Estey EH, Fisher T, Giles F, et al: A Randomized phase II trial of the tyrosine kinase inhibitor PKC412 in patients (pts) with acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes (MDS) characterized by wild-type (WT) or mutated FLT3. Blood 102:2270, 2003 (suppl; abstr)
92. Stone RM, DeAngelo DJ, Klimek V, et al: Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105: 54-60, 2005
93. Nam S, Buettner R, Turkson J, et al: Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A 102:5998-6003, 2005
94. Mohapatra S, Chu B, Wei S, et al: Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res 63:8523-8530, 2003
95. Perrotti D, Neviani P: Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 27:159-168, 2008
96. Turkson J, Ryan D, Kim JS, et al: Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 276:45443-45455, 2001
97. Turkson J, Kim JS, Zhang S, et al: Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 3:261-269, 2004
98. Coppelli FM, Grandis JR: Oligonucleotides as anticancer agents: From the benchside to the clinic and beyond. Curr Pharm Des 11:2825-2840, 2005
99. Gleave ME, Monia BP: Antisense therapy for cancer. Nat Rev Cancer 5:468-479, 2005
100. Lee SO, Lou W, Qureshi KM, et al: RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 60:303-309, 2004
101. Jing N, Sha W, Li Y, et al: Rational drug design of G-quartet DNA as anti-cancer agents. Curr Pharm Des 11:2841-2854, 2005
102. Battle TE, Frank DA: STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1. Blood 102:3016-3024, 2003
103. Wetzler M, Brady MT, Tracy E, et al: Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res 12:6817-6825, 2006
104. Wetzler M, Earp JC, Brady MT, et al: Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity: Pharmacodynamic drug-drug interaction modeling. Clin Cancer Res 13:2261-2270, 2007
105. Hayashi T, Hideshima T, Akiyama M, et al: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 1:851-860, 2002
106. Cheng HY, Li P, David M, et al: Arsenic inhibition of the JAK-STAT pathway. Oncogene 23: 3603-3612, 2004
107. Parmar S, Rundhaugen LM, Boehlke L, et al: Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res 28:909-919, 2004
108. Turkson J, Zhang S, Palmer J, et al: Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3:1533-1542, 2004
109. Turkson J, Zhang S, Mora LB, et al: A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 280:32979-32988, 2005
110. Chen CY, Tsay W, Tang JL, et al: SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer 37:300-305, 2003
111. Watanabe D, Ezoe S, Fujimoto M, et al: Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol 126:726-735, 2004
112. Chim CS, Wong AS, Kwong YL: Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias. Ann Hematol 83:527-532, 2004
113. Johan MF, Bowen DT, Frew ME, et al: Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 129:60-65, 2005
114. Ueda M, Ota J, Yamashita Y, et al: DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome. Br J Haematol 123:288-296, 2003
115. Lehmann S, Bengtzen S, Paul A, et al: Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: Studies of cytotoxicity, apoptosis and the pattern of resistance. Eur J Haematol 66:357-364, 2001
116. Chelbi-Alix MK, Pelicano L: Retinoic acid and interferon signaling cross-talk in normal and RAresistant APL cells. Leukemia 13:1167-1174, 1999
117. Frank DA, Mahajan S, Ritz J: Fludarabineinduced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 5:444-447, 1999
118. Kirkwood JM, Farkas DL, Chakraborty A, et al: Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med 5:11-20, 1999